✦ LIBER ✦

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence

✍ Scribed by Sai-Hong Ignatius Ou

Book ID: 119222876
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 556 KB
Volume: 83
Category: Article
ISSN: 1040-8428
DOI: 10.1016/j.critrevonc.2011.11.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epidermal growth factor receptor tyrosin

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): Simple drugs with a complex mechanism of action?

✍ Nicola Normanno; Monica R. Maiello; Antonella De Luca 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

## Abstract A range of target‐based agents for the treatment of solid tumors are in development. The epidermal growth factor receptor (EGFR) has been identified as a relevant target as it is involved in regulating several cellular functions important in the proliferation and survival of cancer cell

Epidermal growth factor receptor (EGFR)

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)

✍ Elena María Martínez-Navarro; Joseba Rebollo; Ramón González-Manzano; Manuel Sur 📂 Article 📅 2011 🏛 Springer Milan 🌐 Spanish ⚖ 230 KB

Pharmacokinetics of single and multiple

Pharmacokinetics of single and multiple oral doses of zd 1839 (‘Iressa’), a specific epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), in healthy male volunteers

✍ H.C. Swaisland; R. Smith; H. Jones; J. Farebrother; A. Laight 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 184 KB

316 Cetuximab-induced clearance of the e

316 Cetuximab-induced clearance of the epidermal growth factor receptor (EGFR) overcomes resistance of cancer cells to EGFR tyrosine kinase (TK) inhibitors

✍ A. Jimeno; D. Oppenheimer; M.L. Amador; A. Maitra; M. Hidalgo 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Preclinical rationale for a combined tre

Preclinical rationale for a combined treatment with irinotecan and the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (Iressa) in irinotecan-refractory human colon cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 157 KB

ChemInform Abstract: Tyrosine Kinase Inh

ChemInform Abstract: Tyrosine Kinase Inhibitors. Part 9. Synthesis and Evaluation of Fused Tricyclic Quinazoline Analogues as ATP Site Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR).

✍ G. W. REWCASTLE; B. D. PALMER; A. J. BRIDGES; H. D. H. SHOWALTER; L. SUN; J. NEL 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 32 KB